AV BlockSTAY IINCT06707662
Left Septal Pacing or Left Bundle Branch Pacing to Avoid Left Ventricle Systolic Dysfunction
A study testing Pacemaker and defibrillator in people with AV Block, run by Parc de Salut Mar at 1 site in Spain.
Trial summary
Right ventricular apical pacing (RVAP) can produce left ventricular dysfunction (LVD). Conduction system pacing (CSP) has been used successfully to reverse LVD in patients with left bundle branch block. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- AV Block
- What is being tested?
- Pacemaker and defibrillator
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 siteSpain
- Study dates
- 1 Jan 2025to 1 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age of 18 years or more.
- Preserved or mild deteriorated LVEF (Simpson >40%) assessed by a recent (<1 month before implantation) transthoracic echocardiography.
- Indication for pacing based on the presence of a high degree AVB, and consequently with an anticipated high burden of ventricular pacing (>80%).
- Life expectancy of more than 12 months and capability to understand the protocol, signing informed consent form, and complying with follow-up.
Who cannot join
- Patients with indication for implantable cardioverter defibrillator device.
- Patients with indication for a CRT device, with LVEF <40%.
- Patients with previous severe LVD (Simpson LVEF <30%) and a recovered LVEF.
- History of myocardial infarction/revascularization or cardiac surgery within 6 months before randomization.
- Pregnancy, active cancer treatment, or participation in another clinical trial with active treatment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
Hospital del Mar - IMIM
Barcelona, 08003
Ermengol Vallès, PhD, 0034666437038, ermengolvalles@mac.com
About this study
Official title: Left Septal Pacing or Left Bundle Branch Pacing to Avoid Left Ventricle Systolic Dysfunction. A Multicenter Randomized Trial From the STAY Investigators
Right ventricular apical pacing (RVAP) can produce left ventricular dysfunction (LVD). Conduction system pacing (CSP) has been used successfully to reverse LVD in patients with left bundle branch block. A recent randomized controlled trial (RCT) has demonstrated that CSP, mostly performed with left bundle branch area pacing (LBBAP), can preserve normal ventricular function and heart failure admissions compared to RVAP in the setting of a high burden of ventricular pacing11 (Stay Trial).
Criteria to assess the LBBAP distinguishes those cases in which the LBB is captured (LBBP) from those in which only the muscular septum surrounding the LBB is captured (LVSP). To date, data regarding LVSP to preserve left ventricle ejection fraction (LVEF) is scarce and limited to non-randomized studies.
Read the detailed description
Conventional right ventricular apical pacing (RVAP) can produce electrical and mechanical dysynchrony, which may lead to left ventricle dysfunction (LVD) in up to 12% of patients with normal left ventricle ejection fraction (LVEF). A high burden on RVAP is a major predictor of developing LVD, atrial fibrillation (AF), heart failure (HF), and mortality. CSP is able to preserve a more physiological pattern of cardiac electrical activation, utilizing the native conduction system network, or correcting a bundle branch block morphology in patients with disturbances at a proximal or intermediate level of the conduction system network.
The aim of the study is to demonstrate that LVSP can preserve ventricular function compared to LBBP in patients with preserved or mildly deteriorated LVEF and a high burden of expected ventricular pacing. A second hypothesis is to demonstrate than both LVSP and LBBP are both superior to RVAP.
Study design The STAY II trial is a multi-center, prospective, randomized, parallel, controlled study, comparing 12 months outcomes in a population undergoing pacemaker implantation due to a high degree atrio-ventricular block (AVB). All patients will sign informed consent and will be implanted with a pacemaker in a 1:2 randomized fashion to conventional RVAP vs LBBAP (LBBP or LVSP). Randomization to RVAP or LBBAP will be performed during the pre-procedural antibiotic infusion. Patients allocated in the LBBAP group will be evaluated after the procedure and classified as LBBP or LVSP upon the accomplishment of the accepted criteria for LBBAP (consensus).
Consecutive patients requiring permanent pacemaker implantation due to high degree AVB according to current guidelines will be evaluated for inclusion in the study. All patients need to fit all inclusion criteria and none of the exclusion criteria.
Location of the right ventricle pacing lead. Right ventricle apical pacing (RVAP): Capture of the RV by apex stimulation, generating a QRS with LBBB morphology and superior axis.
Left bundle branch pacing (LBBP): Capture of the LBB in one of its ramifications, generating a QRS with RBBB morphology and variable duration, which depends on the grade of impairment present in the more distal conduction system. The rapid activation of the LBB leads to a short left ventricle activation time (LVAT), less than 80 msec, or a long V6-V1 inter peak time (IPT), more than 44 msec. Several other criteria have been described in order to confirm the LBB capture21,22.
Left ventricle septal pacing (LVSP): Only left septal myocardium is captured, obtaining a variable QRS duration with a RBBB morphology in V1, which often are acceptable in terms of similarity with LBBP, but criteria for LBBP are not met.
Deep septal pacing (DSP): Only deep septal myocardium is captured, obtaining a variable QRS duration and morphology, without a RBBB morphology in V1.
Procedure work-flow
The study arm will be defined by randomization immediately before the implantation. Patients randomized to RVAP group will undergo a regular classical apex ventricular lead. Patients randomized to LBBAP will be implanted as follows:
An EP recording system displaying the 12-leads ECG and at least one channel with intracardiac signals will be used in all cases to allow appropriate measurements and to assess the LBBAP criteria accoding to the 2023 Consensus. The 3 required criteria will be: the QRS morphology in V1, the left ventricle activation time (LVAT) and the interpeak V6 to V1 time (IPT). Other measures will be taken at operators' discretion.
Of importance, LBBAP implantation procedure will be similar for all patients: the CSP lead will be implanted in the left bundle branch area with anatomical guidance. Unipolar stimulation aiming for a "W" pattern in V1 will be performed during septal maping. Operators then will screw the lead, aiming for a moderate drop in the impedance, representing a deep penetration into the septum, together with the conversion of the "W" pattern into a qR or rSR pattern in lead V1. The current of injury (COI) will be additionally used to guide the penetration of the lead.
The cornerstone of this study will be to accept the first location as the final location, as long as unipolar and bipolar thresholds are optimal, and the RBBB pattern in lead V1 remains. To ensure a balanced distribution between LBBP and LVSP, the first operator will not have access to any criteria measurement during the implant procedure, but the morphology in V1. In case of suboptimal thresholds or absence of a RBBB in V1, operator will proceed to implant de lead in a different position. After the procedure investigators will fulfill the Redcap database with all the banned EPRS measurements.
Data collection and data analyses Data will be loaded to an electronic CRF (Redcap) by a local authorized operator after the implantation procedure and during each control visit. Every participant center will have access only to their local patients. Only the PI will have access to all the patients. At the end of the recruitment, all the data will analyzed. Variables will be expressed as mean ± SD or number of cases and proportions according to the variable type (Continuous or discrete). Normality will be tested using the Shapiro-Wilk test. Paired T-test will be used to compare 12 months LVEF and LVEDD vs basal LVEF and LVEDD in each group, and for other continuous variables. Z-test will be used to compare discrete variables. KM analyses and Multivariate analyses searching for predictors will be performed. Statistical analysis will be performed using STATA® version 15.2 for windows (StataCorp LLC, Texas).
- Conditions
- AV Block
- Being tested
- Pacemaker and defibrillator
- Keywords
- Conduction System Pacing, Left bundle branch area pacing, Right ventricle apical pacing, Left septum pacing, Left ventricle ejection fraction, Heart failure
- Medical subject headings
- Atrioventricular Block, Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pacemaker and defibrillatorDevice
Pacemaker implantation, which can be a regular right ventricle apical lead or a LBBAP lead (LBBP or LVSP dependint on the criteria accomplished).
| Study group | Role | What they receive |
|---|---|---|
| Right Ventricle Apical Pacing | Active comparator | Standard location for any pacing lead in the right ventricle Receives: Device: Pacemaker and defibrillator |
| Left bundle branch pacing | Experimental | Stimulation in the Conduction System (righ ventricle) capturing the left budle branch Receives: Device: Pacemaker and defibrillator |
| Left septal pacing | Experimental | Stimulation in the Conduction System (righ ventricle) without capturing the left budle branch Receives: Device: Pacemaker and defibrillator |
What is being measured
The primary outcome is the main question the study is designed to answer.
LVEF evolution
Change in the value (%) of LVEF at 12 months compared to basal
Measured: At 12 months after the pacemaker implantation
Admission due to HF
Hospital admission due to episode of heart failure (new onset HF or worsening from baseline NYHA)
Measured: From date of implantation until the date of first admission due to HF, whichever came first, assessed up to 12 months
Secondary outcomes (2)
LVEED evolution
Change in left ventricle end dyastolic diametre from the baseline, at 12 months from pacemaker implantation
Measured: At 12 months after the pacemaker implantation
Admission due to AF
Hospital admission due to atrial fibrillation (new onset or relapse) after the pacemaker implantation
Measured: From date of implantation until the date of first admission due to AF, whichever came first, assessed up to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Nov 2024
- Study start1 Jan 2025
- Primary completion1 Dec 2026 (estimated)
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for AV BlockStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study arm will be defined by randomization immediately before the implantation. Patients randomized to RVAP group will undergo an apex ventricular lead. In patients receiving a LBBAP CSP lead, the procedure will be anatomicaly guided, aiming for a "W" pattern in V1 during septal maping. Operators then will screw the lead, aiming for a moderate drop in the impedance, together with the conversion of the "W" pattern into a qR or rSR pattern in lead V1. The current of injury (COI) will be additionally used as a guide. The cornerstone of this study will be to accept the first location as the final location, as long as unipolar and bipolar thresholds are optimal, and the RBBB pattern in lead V1 remains. To ensure a balanced distribution between LBBP and LVSP, the first operator will not have access to any criteria measurement during the implant procedure, but the morphology in V1. After the procedure investigators will fulfill the Redcap database with all the banned EPRS measurements.
- Masking
- None (open label)
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Parc de Salut Mar
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ermengol Vallès, Parc de Salut Mar
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06707662
- Sponsor's protocol ID
- 2024/11667/I
- Acronym
- STAY II
- Status last verified
- Feb 2025
- First submitted
- 19 Nov 2024
- Last updated
- 11 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected IPD can be shared
Publications
Gonzalez-Matos CE, Rodriguez-Queralto O, Zaraket F, Jimenez J, Casteigt B, Valles E. Conduction System Stimulation to Avoid Left Ventricle Dysfunction. Circ Arrhythm Electrophysiol. 2024 Feb;17(2):e012473. doi: 10.1161/CIRCEP.123.012473. Epub 2024 Jan 29.
PubMed 38284238
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Left Septal Pacing or Left Bundle Branch Pacing to Avoid Left Ventricle Systolic Dysfunction. A Multicenter Randomized Trial From the STAY Investigators
- ClinicalTrials.gov ID
- NCT06707662
- Acronym / sponsor ID
- STAY II / 2024/11667/I
- Conditions
- AV Block
- Keywords
- Conduction System Pacing, Left bundle branch area pacing, Right ventricle apical pacing, Left septum pacing, Left ventricle ejection fraction, Heart failure
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Parc de Salut MarUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 1 Dec 2026 (estimated)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 27 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Right ventricular apical pacing (RVAP) can produce left ventricular dysfunction (LVD). Conduction system pacing (CSP) has been used successfully to reverse LVD in patients with left bundle branch block. A recent randomized controlled trial (RCT) has demonstrated that CSP, mostly performed with left bundle branch area pacing (LBBAP), can preserve normal ventricular function and heart failure admissions compared to RVAP in the setting of a high burden of ventricular pacing11 (Stay Trial).
Criteria to assess the LBBAP distinguishes those cases in which the LBB is captured (LBBP) from those in which only the muscular septum surrounding the LBB is captured (LVSP). To date, data regarding LVSP to preserve left ventricle ejection fraction (LVEF) is scarce and limited to non-randomized studies.
Detailed description
Conventional right ventricular apical pacing (RVAP) can produce electrical and mechanical dysynchrony, which may lead to left ventricle dysfunction (LVD) in up to 12% of patients with normal left ventricle ejection fraction (LVEF). A high burden on RVAP is a major predictor of developing LVD, atrial fibrillation (AF), heart failure (HF), and mortality. CSP is able to preserve a more physiological pattern of cardiac electrical activation, utilizing the native conduction system network, or correcting a bundle branch block morphology in patients with disturbances at a proximal or intermediate level of the conduction system network.
The aim of the study is to demonstrate that LVSP can preserve ventricular function compared to LBBP in patients with preserved or mildly deteriorated LVEF and a high burden of expected ventricular pacing. A second hypothesis is to demonstrate than both LVSP and LBBP are both superior to RVAP.
Study design The STAY II trial is a multi-center, prospective, randomized, parallel, controlled study, comparing 12 months outcomes in a population undergoing pacemaker implantation due to a high degree atrio-ventricular block (AVB). All patients will sign informed consent and will be implanted with a pacemaker in a 1:2 randomized fashion to conventional RVAP vs LBBAP (LBBP or LVSP). Randomization to RVAP or LBBAP will be performed during the pre-procedural antibiotic infusion. Patients allocated in the LBBAP group will be evaluated after the procedure and classified as LBBP or LVSP upon the accomplishment of the accepted criteria for LBBAP (consensus).
Consecutive patients requiring permanent pacemaker implantation due to high degree AVB according to current guidelines will be evaluated for inclusion in the study. All patients need to fit all inclusion criteria and none of the exclusion criteria.
Location of the right ventricle pacing lead. Right ventricle apical pacing (RVAP): Capture of the RV by apex stimulation, generating a QRS with LBBB morphology and superior axis.
Left bundle branch pacing (LBBP): Capture of the LBB in one of its ramifications, generating a QRS with RBBB morphology and variable duration, which depends on the grade of impairment present in the more distal conduction system. The rapid activation of the LBB leads to a short left ventricle activation time (LVAT), less than 80 msec, or a long V6-V1 inter peak time (IPT), more than 44 msec. Several other criteria have been described in order to confirm the LBB capture21,22.
Left ventricle septal pacing (LVSP): Only left septal myocardium is captured, obtaining a variable QRS duration with a RBBB morphology in V1, which often are acceptable in terms of similarity with LBBP, but criteria for LBBP are not met.
Deep septal pacing (DSP): Only deep septal myocardium is captured, obtaining a variable QRS duration and morphology, without a RBBB morphology in V1.
Procedure work-flow
The study arm will be defined by randomization immediately before the implantation. Patients randomized to RVAP group will undergo a regular classical apex ventricular lead. Patients randomized to LBBAP will be implanted as follows:
An EP recording system displaying the 12-leads ECG and at least one channel with intracardiac signals will be used in all cases to allow appropriate measurements and to assess the LBBAP criteria accoding to the 2023 Consensus. The 3 required criteria will be: the QRS morphology in V1, the left ventricle activation time (LVAT) and the interpeak V6 to V1 time (IPT). Other measures will be taken at operators' discretion.
Of importance, LBBAP implantation procedure will be similar for all patients: the CSP lead will be implanted in the left bundle branch area with anatomical guidance. Unipolar stimulation aiming for a "W" pattern in V1 will be performed during septal maping. Operators then will screw the lead, aiming for a moderate drop in the impedance, representing a deep penetration into the septum, together with the conversion of the "W" pattern into a qR or rSR pattern in lead V1. The current of injury (COI) will be additionally used to guide the penetration of the lead.
The cornerstone of this study will be to accept the first location as the final location, as long as unipolar and bipolar thresholds are optimal, and the RBBB pattern in lead V1 remains. To ensure a balanced distribution between LBBP and LVSP, the first operator will not have access to any criteria measurement during the implant procedure, but the morphology in V1. In case of suboptimal thresholds or absence of a RBBB in V1, operator will proceed to implant de lead in a different position. After the procedure investigators will fulfill the Redcap database with all the banned EPRS measurements.
Data collection and data analyses Data will be loaded to an electronic CRF (Redcap) by a local authorized operator after the implantation procedure and during each control visit. Every participant center will have access only to their local patients. Only the PI will have access to all the patients. At the end of the recruitment, all the data will analyzed. Variables will be expressed as mean ± SD or number of cases and proportions according to the variable type (Continuous or discrete). Normality will be tested using the Shapiro-Wilk test. Paired T-test will be used to compare 12 months LVEF and LVEDD vs basal LVEF and LVEDD in each group, and for other continuous variables. Z-test will be used to compare discrete variables. KM analyses and Multivariate analyses searching for predictors will be performed. Statistical analysis will be performed using STATA® version 15.2 for windows (StataCorp LLC, Texas).
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- The study arm will be defined by randomization immediately before the implantation. Patients randomized to RVAP group will undergo an apex ventricular lead. In patients receiving a LBBAP CSP lead, the procedure will be anatomicaly guided, aiming for a "W" pattern in V1 during septal maping. Operators then will screw the lead, aiming for a moderate drop in the impedance, together with the conversion of the "W" pattern into a qR or rSR pattern in lead V1. The current of injury (COI) will be additionally used as a guide. The cornerstone of this study will be to accept the first location as the final location, as long as unipolar and bipolar thresholds are optimal, and the RBBB pattern in lead V1 remains. To ensure a balanced distribution between LBBP and LVSP, the first operator will not have access to any criteria measurement during the implant procedure, but the morphology in V1. After the procedure investigators will fulfill the Redcap database with all the banned EPRS measurements.
| Arm | Type | Receives |
|---|---|---|
| Right Ventricle Apical Pacing | Active comparator | Device: Pacemaker and defibrillatorStandard location for any pacing lead in the right ventricle |
| Left bundle branch pacing | Experimental | Device: Pacemaker and defibrillatorStimulation in the Conduction System (righ ventricle) capturing the left budle branch |
| Left septal pacing | Experimental | Device: Pacemaker and defibrillatorStimulation in the Conduction System (righ ventricle) without capturing the left budle branch |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age of 18 years or more.
- Preserved or mild deteriorated LVEF (Simpson >40%) assessed by a recent (<1 month before implantation) transthoracic echocardiography.
- Indication for pacing based on the presence of a high degree AVB, and consequently with an anticipated high burden of ventricular pacing (>80%).
- Life expectancy of more than 12 months and capability to understand the protocol, signing informed consent form, and complying with follow-up.
Key exclusion criteria (5 listed)
- Patients with indication for implantable cardioverter defibrillator device.
- Patients with indication for a CRT device, with LVEF <40%.
- Patients with previous severe LVD (Simpson LVEF <30%) and a recovered LVEF.
- History of myocardial infarction/revascularization or cardiac surgery within 6 months before randomization.
- Pregnancy, active cancer treatment, or participation in another clinical trial with active treatment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pacemaker and defibrillatorPacemaker implantation, which can be a regular right ventricle apical lead or a LBBAP lead (LBBP or LVSP dependint on the criteria accomplished). | Device | Left bundle branch pacing, Left septal pacing, Right Ventricle Apical Pacing |
Primary outcome
LVEF evolution
Time frame: At 12 months after the pacemaker implantation
Change in the value (%) of LVEF at 12 months compared to basal
Admission due to HF
Time frame: From date of implantation until the date of first admission due to HF, whichever came first, assessed up to 12 months
Hospital admission due to episode of heart failure (new onset HF or worsening from baseline NYHA)
2 secondary outcomes
LVEED evolution
Time frame: At 12 months after the pacemaker implantation
Admission due to AF
Time frame: From date of implantation until the date of first admission due to AF, whichever came first, assessed up to 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2025.
- Background: PubMed 38284238Gonzalez-Matos CE, Rodriguez-Queralto O, Zaraket F, Jimenez J, Casteigt B, Valles E. Conduction System Stimulation to Avoid Left Ventricle Dysfunction. Circ Arrhythm Electrophysiol. 2024 Feb;17(2):e012473. doi: 10.1161/CIRCEP.123.012473. Epub 2024 Jan 29.
- Individual participant dataSharing planned: Yes. All collected IPD can be shared
Related trials for AV Block
Recruiting
SPIKE FLOW Endocardial Lead Safety and Performance Study
Acute Myocardial Infarction (AMI), Asystole
Not yet recruiting
Belgo-Luxembourg Leadless PM Registry
Bradyarrhythmias, AV Block Complete
Recruiting
Novel Approach to Conduction System Pacing With Use of Ultrasound
Conduction Block, Atrioventricular, Bundle-Branch Block
Active, not recruitingObservational study
AVEIR DR Coverage With Evidence Development (CED) Study
Cardiac Pacemaker, Arrythmia
Not yet recruiting
Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan
Atrial Fibrillation (AF), Atrial Flutter
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pacemaker and defibrillator in people with AV Block, run by Parc de Salut Mar at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ermengol Valles, PhD (0034666437038, ermengolvalles@mac.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
LVEF evolution (time frame: At 12 months after the pacemaker implantation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06707662, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2025.